Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SHR-1703 in Asthma
NCT05042401Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Oct 2021
- Primary completion
- Jun 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-1703 in asthma (4 arms), sponsored by Hengrui. Primary endpoints: Incidence of adverse events of SHR-1703, Severity of adverse events of SHR-1703 and 1 more. Status: unknown.
02
Drugs
SHR-1703
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05042401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05042401.